Shenyang Sunshine Pharmaceutical Co., LTD.
Shenyang Sunshine Pharmaceutical Co., LTD.
Explore linked clinical trials.22 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase I Clinical Study to Evaluate the Safety and Efficacy of 3SC009 Monotherapy for Patients With Advanced Solid Tumors | Advanced Solid Tumors Patients | Not yet recruiting | Phase 1 | 2026-09-11 | NCT07815002 | |
| A Phase II Study of SSGJ-612 Plus a HER2-Targeted ADC in HR-Positive, HER2-Low or HER2-Ultralow Expression Metastatic Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Not yet recruiting | Phase 2 | 2026-08-11 | NCT07757230 | |
| SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors | Locally Advanced (Unresectable) or Metastatic Solid Tumors | Recruiting | Phase 2 | 2026-07-28 | NCT07646626 | |
| A Study of SSS68 Following a Single Subcutaneous Administration in Healthy Adult Participants | Healthy | Not yet recruiting | Phase 1 | 2026-05-26 | NCT07606976 | |
| Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of SSS67 in Healthy Adult Participants Via Single Intravenous Infusion | Healthy | Not yet recruiting | Phase 1 | 2026-03-23 | NCT07487545 | |
| The Study is to Evaluate the Safety and Tolerability of SPGL008 Alone or in Combination With BCG in the Patients With NMIBC, and to Determine the RP2D of SPGL008 Alone or in Combination With BCG.To Evaluate the Preliminary Efficacy of SPGL008 Alone or in Combination With BCG. | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Non-Muscle Invasive Bladder Neoplasms, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, carcinoma, epithelial neoplasm, neoplasm, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder | Not yet recruiting | Phase 1 / Phase 2 | 2026-03-03 | NCT07445308 | |
| Safety, Tolerability, PK and PD of SSS55 in Healthy Subjects | Safety Issues | Recruiting | Phase 1 | 2026-03-02 | NCT07058779 | |
| A Phase I Study of SPGL008 in Subjects With Advanced Malignant Tumors | Advanced Malignant Tumors | Recruiting | Phase 1 | 2026-02-09 | NCT07038005 | |
| A Phase 1 Study of SSGJ-709 in Patients With Advanced Malignant Tumors | Advanced Malignant Tumors | Recruiting | Phase 1 | 2026-01-28 | NCT07016490 | |
| A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients | First-line Advanced NSCLC Patients | Recruiting | Phase 2 | 2025-12-18 | NCT07171606 | |
| A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers | Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, esophageal disorder, intestinal disorder, neoplasm, rectal disorder | Not yet recruiting | Phase 2 | 2025-11-18 | NCT07233850 | |
| SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors | Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, neoplasm | Recruiting | Phase 2 | 2025-08-03 | NCT07022002 | |
| A Phase I Study of SSGJ-612 in Patients With Advanced Solid Tumors | Advanced Malignant Tumors | Recruiting | Phase 1 | 2025-07-25 | NCT07032298 | |
| Phase I Study of HBT-708 for Patients With Advanced Solid Tumors | Advanced Solid Tumors | Recruiting | Phase 1 | 2025-07-11 | NCT06993870 | |
| A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SSS39 Injection in Healthy Chinese Subjects | Safety and Tolerability in Healthy Volunteers | Enrolling by invitation | Phase 1 | 2025-07-10 | NCT07057726 | |
| A Phase 1 Mass Balance Study of [¹⁴C]SSS17 in Healthy Chinese Males | Healthy Subjects (HS) | Not yet recruiting | Phase 1 | 2025-06-25 | NCT07025915 | |
| SSGJ-707 in Advanced Non-Small Cell Lung Cancer | Advanced Non-Small Cell Lung Cancer | Recruiting | Phase 3 | 2025-06-24 | NCT06980272 | |
| Phase IIa Trial of Oral SSS17 for Post-Arthroplasty Anemia | Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Postoperative Anemia | Not yet recruiting | Phase 2 | 2025-06-11 | NCT07007936 | |
| Phase I Study of sss40 Injection for Moderate-to-Severe Bone Metastatic Cancer Pain | Cancer Pain, Neurologic Manifestations, Pain, Pathological Conditions, Signs and Symptoms, Signs and Symptoms | Recruiting | Phase 1 / Phase 2 | 2025-06-06 | NCT07008703 | |
| Safety, Tolerability, and Pharmacokinetic Characteristics of SSS11 in Patients With Gout and Hyperuricemia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Crystal Arthropathies, Hyperuricemia, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, arthritic joint disease, arthropathy, gout, hereditary disease, inborn disorder of purine or pyrimidine metabolism, inborn errors of metabolism, metabolic disease, musculoskeletal system disorder, rheumatic disorder | Recruiting | Phase 1 | 2025-05-28 | NCT06629376 | |
| A Phase I Clinical Study of SSS59 Monotherapy in Patients With Advanced Malignant Tumors | neoplasm | Recruiting | Phase 1 | 2025-04-29 | NCT06944444 | |
| Study of SSS06 for Chemotherapy-Induced Anemia in Non-Myeloid Malignancies | Chemotherapy-induced Anemia; Non-myeloid Malignancies | Not yet recruiting | Phase 2 | 2025-03-03 | NCT06854276 |